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MetabolismCardiovascular disease is common in patients with diabetes and is a signiﬁcant contributor to the high
mortality rates associated with diabetes. Heart failure is common in diabetic patients, even in the absence of
coronary artery disease or hypertension, an entity known as diabetic cardiomyopathy. Evidence indicates that
myocardial metabolism is altered in diabetes, which likely contributes to contractile dysfunction and
ventricular failure. The mitochondria are the center of metabolism, and recent data suggests that
mitochondrial dysfunction may play a critical role in the pathogenesis of diabetic cardiomyopathy. This
review summarizes many of the potential mechanisms that lead to mitochondrial dysfunction in the diabetic
heart. This article is part of a Special Issue entitled: Mitochondria and Cardioprotection.hondria and Cardioprotection.
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The prevalence of Type 2 diabetes is reaching pandemic
proportions, with estimates that by the year 2025 nearly 300
million adults will be affected by diabetes mellitus [1,2]. Cardio-
vascular disease is the leading cause of mortality in patients with
diabetes mellitus [3,4]. Patients with diabetes are at increased risk
of hypertension, coronary artery disease and mortality following
myocardial infarction [5,6]. However, it has also been demonstrated
that diabetic patients develop heart failure in the absence of risk
factors such as hypertension and coronary artery disease [6–8]. The
term “diabetic cardiomyopathy” is now used to refer to ventricular
dysfunction in diabetic patients that is out of proportion to their
underlying vascular disease [9,10].
A number of investigators have used animal models to evaluate
the mechanistic basis for cardiac dysfunction in the setting of
obesity and Type 2 diabetes. The most commonly used models
involve defects in leptin signaling, which is a critical hormone
regulating energy intake and expenditure. These models include db/
db mice and Zucker Diabetic Fatty (ZDF) rats (leptin receptor
mutation) and ob/ob mice (leptin deﬁciency). All of these animals
have the common phenotype of obesity, insulin resistance and
hyperglycemia to varying degrees [11–13]. UCP-DTA animals, used
less frequently, are a model in which the brown adipose tissue isablated, leading to decreased metabolic rate, increased appetite,
obesity, and progression from insulin resistance to diabetes [14].
Importantly, these animal models are resistant to development of
atherosclerosis, allowing investigators to speciﬁcally evaluate heart
failure without the presence of coronary artery disease [15,16].
Echocardiographic data in these animal models has also demon-
strated diastolic and later systolic dysfunction, similar to humans
[17–21]. Thus, animal models support the human data that diabetes
is associated with structural and functional abnormalities of the
myocardium, leading to diabetic cardiomyopathy.
2. Metabolic abnormalities in the diabetic heart
Emerging data demonstrates that cardiac dysfunction in diabetic
patients is linked to metabolic abnormalities. Obesity and diabetes are
characterized by high levels of circulating fatty acids which results in
increased cardiac fatty acid uptake, storage, and metabolism [22,23].
Fatty acids taken up by the cardiomyocyte are normally catabolized in
mitochondrial and in some circumstances, peroxisomal fatty acid β-
oxidation (FAO) pathways. Fatty acids are also incorporated into
triglycerides (TAG). There is a dynamic ﬂux through the TAG pool, and
recent data demonstrates that many of the fatty acids that are
ultimately oxidized through β-oxidation ﬂux through TAG [24]. In
addition Banke et al. demonstrated evidence that peroxisome
proliferator-activated receptor alpha (PPARα), which is upregulated
in diabetic hearts, plays a role in modulating TAG ﬂux [24]. The heart
does not normally store signiﬁcant amounts of lipid, but triglycerides
can accumulatewhen fatty acid supply is high. Myocardial triglyceride
content is notably increased in animal models and humans with
obesity and Type 2 diabetes compared to healthy controls [25–27].
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fatty acid) normally varies in a dynamic manner to meet the
tremendous energy needs of the mammalian heart. In uncontrolled
diabetes, cardiac energy substrate preference becomes constrained
because of the need for insulin for myocardial glucose uptake. Glucose
utilization in the diabetic heart is diminished at least in part because
of insulin resistance, impaired pyruvate dehydrogenase activity, and
reduced glucose transporter (e.g. Glut4) content. Thus, the diabetic
heart relies almost exclusively on mitochondrial FAO for ATP
synthesis. This reliance on FAO has potentially detrimental conse-
quences, among which include impaired mitochondrial respiratory
function.
3. Evidence for mitochondrial dysfunction in diabetes
Mitochondria are the center of fatty acid and glucose metabolism
and thus are highly likely to be impacted by impaired metabolism
associated with diabetes. A number of investigators have demon-
strated mitochondrial abnormalities in skeletal muscle of insulin-
resistant and diabetic humans. In two independent gene expression
analyses, gene targets associated with mitochondrial oxidative
phosphorylation (OXPHOS) have been reduced [28,29]. Both groups
found a decrease in peroxisome-proliferator-activated receptor
(PPAR) gamma, co-activator-1α (PGC-1α), a master metabolic
regulator that coordinates gene expression for pathways involved in
mitochondrial biogenesis and respiratory function [30]. Additional
studies of mitochondrial function and morphology in human skeletal
muscle further support a connection between mitochondrial dys-
function and diabetes. Shulman and colleagues demonstrated a
reduction in ATP synthesis and mitochondrial content in severely
insulin-resistant offspring of Type 2 diabetics [31,32]. In addition,
Kelley et al., noted impaired mitochondrial enzyme activities and
reduced size and number of skeletal muscle mitochondria from
diabetic patients [33,34]. Pagel-Langenickel et al. demonstrated in
isolated myocytes that disruption in insulin signaling results in
dysregulation of mitochondrial biogenesis and impairment in mito-
chondrial membrane potential. These changes were restored by
treatment with pioglitazone to improve insulin signaling and by
overexpression of PGC-1α [35]. Taken together, these data strongly
implicate impaired mitochondrial function in skeletal muscle of
rodents and human diabetic patients.
Cardiac mitochondrial function has been less well studied in
human subjects, likely secondary to difﬁculty obtaining appropriate
human heart tissue samples for in depth investigations of mito-
chondrial functional capacity. However, a number of studies provide
indirect evidence for altered cardiac mitochondrial function in
diabetic patients. Diamant et al. studied high-energy phosphate
metabolism and cardiac function in asymptomatic well-controlled
diabetic men and controls using MRI and 31P nuclear magnetic
resonance spectroscopy. They demonstrated a reduction in multiple
indexes of diastolic function by MRI in the diabetic patients; these
functional changes were associated with a reduction in the cardiac
phosphocreatine/ATP ratios [36]. More recently, the high-energy
phosphate metabolism data was not conﬁrmed in a study of non-
ischemic diabetic cardiomyopathy using MRI and PET imaging;
however, there was also less difference in substrate metabolism
changes in the study groups, which the authors suggested might
contribute to the discrepancy in data [37]. A reduction in cardiac
phosphocreatine/ATP ratios has also been demonstrated in hearts of
diabetic patients with normal cardiac function by echocardiography
[38], suggesting that changes in mitochondrial function may precede
the reduction in contractility. Finally, Anderson et al. demonstrated
in the left atrial appendage tissue from Type 2 diabetic patients
undergoing coronary bypass surgery that mitochondrial respiratory
function was impaired and hydrogen peroxide emission was
increased, suggesting an increase in oxidative stress [39]. Togetherwith human data demonstrating altered lipid metabolism, these
studies strongly implicate mitochondrial dysfunction in the human
diabetic heart.
In contrast with human data, mitochondrial function has been
directly studied in multiple animal models of diabetes (Type 1 and
Type 2). In a model of chronic Type 1 diabetes (OVE26 mice), it was
demonstrated that diabetic mice had evidence of mitochondrial
biogenesis that was coupled to a reduction in mitochondrial
function and mitochondrial ultrastructural abnormalities [40].
Animal models (db/db and ob/ob) of Type 2 diabetes have also
provided evidence for reduced State 3 (ADP-stimulated or maximal)
respiration [41,42]. Additionally, target genes involved in mitochon-
drial function were noted to be decreased in ob/ob mice [42].
Furthermore, there is evidence for increased cardiac mitochondrial
number (mitochondrial biogenesis) and ultrastructural defects by
electron microscopy in two different obese animal models of insulin
resistance and diabetes (UCP-DTA and ob/ob mice) [42,43]. More
recently, Boudina et al. have also demonstrated a relationship
between impaired cardiac insulin signaling and altered mitochon-
drial energetics by using mice with a cardiac-speciﬁc deletion of the
insulin receptor [44]. The results from using this approach suggest
that impairments in the insulin signaling cascade in the absence of
obesity or systemic metabolic abnormalities can affect mitochon-
drial form and function. In summary, the animal model investiga-
tions provide conclusive evidence that mitochondrial function is
impaired in the hearts of animals with insulin resistance and
diabetes. In the following sections, the potential mechanisms that
contribute to mitochondrial impairment will be discussed.
4. Mechanisms of mitochondrial dysfunction in
diabetic cardiomyopathy (See Figure 1 overview)
4.1. Altered energy metabolism (including uncoupling)
As noted above, the heart has a high and continuous demand for
oxidative metabolism in order to keep up with ATP production.
Accordingly, the cardiomyocyte has a relatively high number of
mitochondria compared to other tissues (approximately 40% of
cardiomyocyte volume is mitochondria). Approximately 70% of the
ATP generated by the heart is generated via oxidation of fatty acids. In
healthy hearts, the rate of oxidative phosphorylation is tightly linked
to the rate of ATP hydrolysis so that ATP content remains constant.
Thus, the heart relies on ﬂexibility in its fuel source, preferentially
using fatty acids or carbohydrates depending on physiologic or
pathologic demands, including changes in workload, energy substrate
supply, and oxygen supply to the heart. For example, during
pathologic hypertrophy, heart failure and myocardial infarction the
heart shifts fuel preference towards glucose oxidation [45]. This shift
in fuel preference allows for continued ATP production with less
oxygen consumed.
The diabetic heart has increased rates of FAO and decreased rates
of glucose oxidation [46,47]. Furthermore, the ability to shift fuel
preference is constrained. These changes in FAO rates have been
demonstrated inmultiple mousemodels [46] and in ZDF rats [48]. The
increase in fatty acid oxidative capacity is mediated at least in part by
increased activity of the nuclear receptor transcription factor, PPARα
[49,50]. PPARα is an important transcriptional regulator of fatty acid
uptake and oxidation that controls expression of virtually every
enzyme involved in the fatty acid utilization pathways [50,51]. Mouse
models in which PPARα is deﬁcient (PPARα−/− mice) have reduced
expression of genes involved in fatty acid utilization and reduced
myocardial FAO rates [52–54]. In contrast, transgenic overexpression
of PPARα in the heart (MHC-PPARα mice) results in markedly
increased rates of fatty acid uptake, oxidation and TAG storage [55,56].
Interestingly, we recently demonstrated that MHC-PPARα mice have
mitochondrial ultrastructural abnormalities that were rescued when
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lipase (LpL) [57].We found a reduction in several enzymes involved in
mitochondrial OXPHOS, as well as a reduction in the PPARα co-
activator PGC-1α in MHC-PPARα hearts; loss of LpL returned gene
expression levels to normal [57]. PGC-1α is also known to co-activate
other transcription factors that regulate mitochondrial number and
mitochondrial OXPHOS [30,58]. These data suggest that excessive
fatty acid uptake has detrimental consequences on mitochondrial
OXPHOS genes and mitochondrial ultrastructure. The speciﬁc role of
PGC-1α in this process remains unclear. It has been noted by several
investigators that PGC-1α is increased in insulin-resistant animal
models [43,46]. However, this may be a temporal phenomenon, as
PGC-1α has also been found to be downregulated at later stages of
diabetes (Duncan, unpublished data) [46].
The increase in FAO may be energetically detrimental, as there is
a higher oxygen cost for oxidizing more fatty acids. Indeed, acute
lipid infusion in healthy dogs is known to cause increased oxygenFig. 1. Mechanisms contributing to mitochondrial dysfunction. Insulin resistance and diabe
increased fatty acid (FA) uptake via FA transporters (e.g., FATP, CD36), in part mediated by in
to increased FAO and oxygen consumption (VO2) (1B). In addition, proton transfer via u
contributing to cardiac inefﬁciency (1C). Increased FAO and oxidative phosphorlyation and i
(O2•) production at complexes I and III (2), in addition a reduction in ROS scavenging enzym
membranes is altered (3), impacting TCA cycle enzyme activity and ATP production. Em
biogenesis, perhaps mediated in part by PGC-1α, as well as decreased levels of important re
(Dlp) (4). Mitochondrial membrane phospholipid content is altered, with evidence of de
modalities (5).consumption [59,60]. Animal models of Type 2 diabetes have
similarly shown a reduction in cardiac efﬁciency, with increased
myocardial oxygen consumption (VO2) associated with increased
FAO [42,46,47,61,62]. Furthermore, we noted decreased ATP/oxygen
consumption ratios in UCP-DTA mice, a model of diabetes,
indicating reduced mitochondrial efﬁciency [43]. Finally, Peterson
et al. have noted that obesity and insulin resistance affect cardiac
efﬁciency in young women [63], suggesting similar physiology in
the human diabetic heart. The increased demand for oxidizing fatty
acids and the reduction in cardiac efﬁciency may contribute to
contractile dysfunction in the diabetic heart. Furthermore, the
altered substrate ﬂexibility and the change in oxygen consumption
potentially may contribute to increased mortality following ische-
mic damage in diabetic patients.
One potential explanation for increased VO2 and reduced cardiac
efﬁciency (or mitochondrial ATP production for amount of oxygen
consumed) is that mitochondrial uncoupling is increased. Studiestes lead to increased circulating free fatty acids (FFA) and triglyceride (TAG). There is
creased activity of PPARα and PGC-1α (1A). Increased FA uptake and PPARα contribute
ncoupling proteins (UCPs) contributes to uncoupling, reducing ATP production and
mpairment in the electron transport chain contribute to increased ROS and superoxide
es may contribute to oxidative protein damage. Calcium transport across mitochondrial
erging data suggest altered mitochondrial dynamics, with evidence of mitochondrial
gulators of mitochondrial ﬁssion, such as mitofusin 2 (Mfn) and dynamin-like protein
creased cardiolipin content, which may impact mitochondrial function via multiple
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reduction in gene expression for multiple of the OXPHOS complexes,
indicating that oxygen was consumed in the setting of mitochondrial
deﬁcits. These data suggest that mitochondrial uncoupling is
increased resulting in decreased ATP/oxygen ratios.
Mitochondrial VO2 is normally tightly coupled to ATP synthesis.
Substrate oxidation results in reducing equivalents that deliver
electrons across the mitochondrial electron transport chain. The
energy that is produced during electron transfer is used to create an
electrochemical gradient by pumping hydrogen ions (H+) from the
mitochondrial matrix to the intermembrane space. These H+
generally reenter the matrix via the F0F1-ATPase, which uses the
energy to produce ATP from ADP. It is possible for H+ to bypass the
F0F1-ATPase, resulting in oxygen consumption that is not coupled to
ATP production via the H+-translocase uncoupling protein (UCP)-1
[64]. There are four additional homologs for UCP1 (UCP2, 3, 4 and 5)
[65]. Two of these homologs (UCP2 and UCP3) are also thought to
mediate proton transfer back into the mitochondrial matrix, resulting
in mitochondrial uncoupling [66–69]. Both UCP2 and UCP3 are
expressed in the heart, although their speciﬁc role remains unclear
[70,71].
Recently, Boudina et al. demonstrated mitochondrial uncoupling
in db/db mouse hearts [61]. They noted an increase in respiration in
the setting of oligomycin, an inhibitor of the F0F1-ATPase and an
increase in proton leak from cardiac mitochondria isolated from db/db
mice. Adding guanosine diphosphate, an inhibitor of UCPs, resulted in
restoration of proton leak to wild-type levels, strongly suggesting that
the increased uncoupling was mediated by UCPs. A second potential
mediator of mitochondrial uncoupling is the adenine nucleotide
translocator (ANT). Boudina et al. also found that atractyloside, an
inhibitor of ANT-mediated uncoupling, altered proton leak in db/db
mitochondria, suggesting that ANT may also contribute to uncoupling
in diabetic hearts [61].
4.2. Oxidative stress
Mitochondria are a major source of reactive oxygen species (ROS)
production. It is estimated that approximately 90% of basal cellular
ROS is produced by the mitochondria in tissues with high rates of
respiration, such as cardiomyocytes [72]. The electron transport chain
generates superoxide radicals as an inevitable by-product at complex I
and complex III in the respiratory chain [73,74]. Although the
mitochondria produce a large fraction of ROS, there are mechanisms
that also likely contribute to increased cytosolic ROS in diabetes,
including development of advanced glycation end (AGE) products and
modulation of NADPH oxidase [75,76]. Superoxide (O2•) within the
mitochondrial intermembrane space, or in the cytosol, forms
hydrogen peroxide (H2O2), which is involved in subsequent oxygen
sensing modiﬁcation via stabilization of the transcription factor
hypoxia inducible factor-1 alpha (HIF-1α) [77]. Thus, ROS generated
by the mitochondria have the ability to modify multiple additional
physiologic pathways. ROS can directly damage proteins by oxidation,
or they can oxidize lipids to form lipid peroxidation products, which
can induce protein or phospholipid damage. ROS are also involved in
DNA damage, in particular damage tomitochondrial DNA [78]. Finally,
ROS can generate peroxynitrite from nitric oxide (NO), causing
intracellular nitrosylation [79] and further impairment of mitochon-
drial respiration. Mitochondria are also armed with ROS defense
mechanisms, such that intrinsic ROS production is almost completely
eliminated at baseline [80]. Manganese superoxide dismutase
(MnSOD) facilitates the conversion of superoxide to H2O2, protecting
cells from superoxide-induced damage [80]. Reduced glutathione
(GSH) scavenges hydroxyl radicals preventing a free radical chain
reaction [81,82]. Interestingly, recent proteomic data suggests that
cytosolic ROS defense mechanisms may be more signiﬁcantly
impacted by diabetes than mitochondrial defense mechanisms.Johnson et al. reported a reduction in cytosolic ROS scavenging
proteins in diabetic rat tissue [83]. Thus, deﬁciencies in the
antioxidant defense system may also contribute to oxidative damage
in cells.
Oxidative stress has been implicated in the pathophysiology of
diabetes and its complications [84,85]. Cytosolic ROS production
may play a role in inducing mitochondrial damage and even
enhance mitochondrial ROS production. Cytosolic ROS are known to
induce opening of the mitochondrial permeability transition pore
(MPTP) during ischemia [86]. One proposed mechanisms for MPTP
opening in diabetic kidney disease is the production of AGE
associated with hyperglycemia, which result in AGE receptor
(RAGE)-induced production of cytosolic ROS, which in turn result
in opening of the MPTP [75]. Recently, high levels of AGE products
have been found in cardiac tissue of diabetic patients [87].
Furthermore, metformin, an anti-diabetic medication, has been
shown to inhibit opening of the MPTP during ischemia reperfusion
in diabetic rats [88].
Brownlee and colleagues have generated signiﬁcant evidence
that mitochondrial ROS activate multiple pathways for cellular
damage in the setting of hyperglycemia [89–92]. An increase in 3-
nitrotyrosine in association with increased cell death has been
noted in human myocardial samples [93], as well as in a
streptozotocin (STZ)-induced model of Type 1 diabetes [94]. In
addition, there is evidence for tyrosine nitration of cardiac
mitochondrial proteins in mice with Type 1 diabetes [79]. These
data implicate peroxynitrite damage pathways in diabetic cardio-
myopathy. Indeed, Cai et al. demonstrated a reduction in nitrosative
damage with overexpression of metallothionein, an antioxidant
protein, in STZ-treated mice [94]. In a different model of Type 1
diabetes (OVE26 mice), metallothionein overexpression in the heart
rescued contractile dysfunction and returned levels of oxidized
glutathione (GSSG) to normal [95]. Other studies have demonstrat-
ed that overexpression of superoxide scavengers, such as catalase
and MnSOD, in mouse models of Type 1 diabetes, results in
preservation of myocardial function and mitochondrial morphology
[96,97]. Data from Type 2 diabetic models is more limited. Boudina
et al. have reported an increase in mitochondrial H2O2 in db/db mice
in association with increased levels of MnSOD, suggesting that there
is an increase in ROS production [61]. In addition, catalase
overexpression in obese Ay mice resulted in normalization of
cardiomyocyte contractility [96]. Thus, it appears that ROS mech-
anisms may be similar in Type 1 and Type 2 diabetic hearts. Taken
together, these data implicate multiple pathways for oxidative
stress in the diabetic myocardium and suggest that each of these
may contribute to myocardial dysfunction.
4.3. Impaired mitochondrial calcium handling
We have already discussed the proton gradient that is generated
by oxidative phosphorylation in the electron transport chain. This
proton gradient, also known as the transmembrane potential, is
required for ATP production, but it also plays an important role in
driving calcium accumulation in mitochondria. A uniporter carries
calcium down the electrochemical gradient, and the accumulated
calcium is removed via a Na+/Ca2+ exchanger. Calcium uptake into
the mitochondrion now appears to be important for activation of the
tricarboxylic acid (TCA) cycle and possibly for increasing ATP
production (see review [98]). The relative contribution of calcium
uptake in ATP production remains to be deﬁned in vivo. Nevertheless,
it is proposed that calcium transfer from cytosol to mitochondria may
represent a mechanism for coordinating ATP supply and demand for
cardiomyocyte contraction [98,99]. Mitochondrial calcium uptake
may also act as a spatial buffering system, removing calcium locally
and modulating cytosolic calcium concentrations, thus regulating
activity of calcium-dependent processes [100]. The mitochondria lie
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reticulum calcium release sites, thus mitochondrial calcium uptake
likely plays a role in regulating calcium signaling from these
organelles as well [98]. Interestingly, there may also be a role for
mitochondrial and nuclear communication via calcium signaling.
PGC-1α is known to play an important role in mitochondrial
biogenesis and regulation of respiratory activity. PGC-1α is regulated
in part by calcium-dependent processes [30] and has been demon-
strated to play a role in calcium signaling and calcium mediated cell
death [101]. Given the potential impact of calcium signaling on
mitochondrial energy metabolism, it is possible that altered calcium
handling contributes to diabetic cardiomyopathy.
There are limited studies of mitochondrial calcium handling
defects in models of Type 2 diabetes. Fauconnier and co-workers
demonstrated impaired calcium handling in cardiomyocytes from
ob/ob mice [102]. In addition Belke et al. found a reduction in
calcium levels in isolated cardiomyocytes from db/db animals and
reduction in the rate of calcium decay, suggesting impaired
mitochondrial calcium uptake [103]. Data on mitochondrial calcium
handling deﬁcits is more robust in Type 1 diabetes models. STZ-
induced diabetic rats have lower rates of mitochondrial calcium
uptake, a change that was associated with development of
hyperglycemia [104]. Another cause of reduced mitochondrial
calcium is increased opening of the mitochondrial permeability
transition pore (MPTP), resulting in release of accumulated calcium.
In STZ-induced diabetic rats, it was observed that calcium uptake
was similar in control versus diabetic animals but that mitochondria
in diabetic hearts were unable to retain the accumulated calcium.
This phenomenon was not seen in the presence of an MPTP
inhibitor, cylcosporin [105]. Thus, the data in these different animal
models supports the notion that mitochondrial calcium handling is
impaired in diabetic myocardium, resulting in compromised energy
metabolism and thus reduced contractility.
4.4. Cell death
A number of investigators have implicated cell death in the
pathogenesis of diabetic cardiomyopathy in patients and in animal
models [106–108]. The mechanisms contributing to apoptosis are not
entirely clear but likely involve mitochondrial and endoplasmic
reticulum–stress responses, and oxidative stress. Cai et al. have
demonstrated that metallothionein treatment of STZ-treated mice
was able to reduce mitochondrial oxidative stress and attenuate cell
death [109]. Li et al. demonstrated in STZ-induced diabetic rats that
protein and mRNA expression of caspase 12 and Grp78 were inducedFig. 2. Evidence of mitochondrial biogenesis and ultrastructural changes in diabetic myoc
transgenic (NTG) and diabetic, UCP-DTA hearts showing increased mitochondrial num
accumulation (right).in association with evidence of apoptosis, suggesting activation of an
ER-stress response that contributed to cell death. Additionally,
evidence of mitochondrial-induced apoptosis has been generated in
experimental animals. Williamson et al. reported evidence of
increased caspase activity in diabetic (STZ-treated) mice in associa-
tion with changes in mitochondrial membrane potential and MPTP
opening, speciﬁcally in the interﬁbrillar mitochondrial population
[110]. Additional reports from this same group have documented
proteomic differences in mitochondrial proteins, including altered
ANT1 and antioxidant expression, two potential contributors to
mitochondrial-induced cell death. They have also noted changes in
oxidative protein damage and mitochondrial cardiolipin content,
which may alter mitochondrial membrane integrity and contribute to
mitochondrial-induced apoptosis [111,112].
4.5. Altered mitochondrial dynamics and biogenesis
Recent studies by our group and others have demonstrated an
increase in cardiac mitochondria in multiple mouse models of
diabetes [42,43,113]. In each of these models, despite mitochondrial
biogenesis, mitochondrial respiratory function and/or ATP produc-
tion was impaired. Thus, mitochondrial biogenesis was not coupled
to an increase in mitochondrial function. These studies have raised
the question as to whether mitochondrial biogenesis is an adaptive
or maladaptive process. We observed in UCP-DTA mice an increase
in PGC-1α expression in insulin-resistant animals [43]. In addition,
there was an absence of mitochondrial biogenesis in UCP-DTA
animals in a PGC-1α-deﬁcient background, suggesting that PGC-1α
was necessary for the increase in mitochondrial number. However,
PGC-1α was not increased in ob/ob animals, despite an increase in
mitochondrial DNA and mitochondrial number [42]. In addition, we
have also observed a downregulation of PGC-1α with the onset of
overt diabetes in UCP-DTA animals (unpublished data), despite
evidence of persistently increased mitochondrial number (Fig. 2).
These observations suggest that PGC-1α-independent mechanisms
may play a role in the mitochondrial biogenic response and that
upregulation of PGC-1α is a temporal phenomenon, possibly related
to hyperglycemia. The speciﬁc role for mitochondrial biogenesis in
the diabetic heart remains unclear. While it is tempting to speculate
that excess fatty acid uptake stimulates an increase in mitochondrial
number, it is clear from these animal models that mitochondrial
respiratory capacity is not enhanced [42,43,113]. It is possible
perhaps that mitochondrial proliferation itself is a trigger for
mitochondrial dysfunction, but at this time there is no clear data
to support this hypothesis.ardium. Representative electron micrographic images of papillary muscle from non-
ber. Arrows represent areas of mitochondrial architecture damage (left) and lipid
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shape and subcellular distribution. The number and morphology of
mitochondria are regulated by rates of mitochondrial ﬁssion and
fusion. Thus, the change in mitochondrial number in diabetic hearts
may reﬂect alterations in rates of mitochondrial ﬁssion and/or fusion.
In addition, mitochondrial ﬁssion and fusion have also recently been
associated with mitochondrial fragmentation and apoptosis
[114,115]. Thus, an additional potential mechanism for mitochondrial
impairment and contractile dysfunctionmay be alteredmitochondrial
ﬁssion/fusion machinery. There is limited data regarding the role of
mitochondrial dynamics in diabetes. Impaired mitochondrial ﬁssion
has been implicated in mitochondrial failure in pancreatic β-cells
[116,117]. Mitofusin 2, an important regulator of mitochondrial
fusion, was reduced in skeletal muscle of obese ZDF rats [118].
Studies of cardiac mitochondrial ﬁssion and fusion are even more
limited. In isolated cardiac cells, Yu et al. demonstrated that
mitochondrial ﬁssion contributed to high-glucose-induced apoptosis
[119]. In multiple different cardiac-derived cells exposed to high
glucose, it was demonstrated that mitochondria were fragmented and
that cell death was increased. Inhibition of mitochondrial ﬁssion, by
overexpression of a dominant-negative DLP1 (dynamin-like protein)
protein, resulted in normalization of mitochondrial morphology, ROS
levels and cell death [119]. The role of mitochondrial ﬁssion and
fusion in intact animals remains to be elucidated.4.6. Mitochondrial lipid content
Mitochondrial membranes, like those of other organelles, are
comprised of a lipid bilayer. The mitochondria are characterized by a
highly specialized phospholipid, cardiolipin, which is almost exclu-
sively localized to the inner mitochondrial membrane where it is
synthesized [120]. Evidence suggests that cardiolipin plays a key role
in regulating mitochondrial bioenergetics by optimizing activities of
various mitochondrial inner membrane proteins involved in OXPHOS
[121–123]. Cardiolipin has a role in maintaining contact sites between
the inner and outer mitochondrial membranes [124]. Cardiolipin has
also been noted to be required for electron transfer in the
mitochondrial respiratory chain [125]. Because of its location in the
inner mitochondrial membrane, cardiolipin interacts with numerous
other innermembrane proteins to optimizemitochondrial respiratory
activity and anion transport. It is also speculated to play a role in
mitochondrial ﬁssion and fusion (see reviews [120,122]). In addition,
cardiolipin is susceptible to oxidative damage by ROS and has been
shown to play a critical role in calcium handling and cell death [120].
The importance of cardiolipin is underscored by the pathology seen in
Barth syndrome, an X-linked recessive disorder with mutations in
tafazzin, an essential enzyme for cardiolipin remodeling; patients
with Barth syndrome suffer from variable degrees mitochondrial
dysfunction and cardiomyopathy [126]. Alterations in cardiolipin
content or composition have also been demonstrated in several other
disease states [127]. Given the dramatic changes in lipid uptake and
storage seen in diabetic patients, it has been hypothesized that
mitochondrial lipidsmay also be altered and that this could contribute
to mitochondrial dysfunction. Thus far, there are limited data
regarding cardiolipin content in models of diabetes. Han et al. found
that both ob/ob mice and STZ-induced diabetic mice had signiﬁcantly
decreased levels of cardiolipin in the myocardium [128]. More
recently, it was demonstrated that STZ-treated mice had signiﬁcant
changes to the interﬁbrillar mitochondrial population, which included
reduced mitochondrial size, cardiolipin content and electron trans-
port activity [112]. These ﬁndings were associated with a decrease in
contractile function using an isolated working heart model [112].
Thus, these data suggest that diabetes is another pathologic state in
which mitochondrial cardiolipin content is altered, which may have
important implications for altered mitochondrial bioenergetics.5. Conclusion
The heart requires a continuous source of substrate and optimal
mitochondrial metabolism to meet its high-energy demands. In the
setting of diabetes, substrate ﬂexibility is limited and mitochondrial
function is compromised, which we propose results in contractile
dysfunction and thus contributes to diabetic cardiomyopathy. This
review summarizes multiple possible mechanisms that may contrib-
ute to mitochondrial dysfunction in the diabetic heart. Many of these
mechanisms have an impact that overlaps with those of other
systems. Thus, more than likely, a combination of these different
mechanisms play a role in the decline of mitochondrial function
during the progression from insulin resistance to full blown diabetes
and during the progression from compensated to decompensated
heart failure. As the diabetes pandemic continues and cardiovascular
disease rates increase, it is imperative that investigators pursue
additional mechanistic studies in human subjects as well as begin to
explore potential therapies targeted at speciﬁc mitochondrial defects
that may contribute to diabetic cardiomyopathy.
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